Procyon Advisors LLC Raises Stock Holdings in Bristol Myers Squibb Company $BMY

Procyon Advisors LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 33.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 35,801 shares of the biopharmaceutical company’s stock after acquiring an additional 8,907 shares during the period. Procyon Advisors LLC’s holdings in Bristol Myers Squibb were worth $1,615,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Trifecta Capital Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter worth $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the 2nd quarter worth about $25,000. Harbor Capital Advisors Inc. lifted its holdings in Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares in the last quarter. REAP Financial Group LLC boosted its position in Bristol Myers Squibb by 202.8% in the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 428 shares during the period. Finally, DHJJ Financial Advisors Ltd. grew its stake in Bristol Myers Squibb by 51.9% in the 2nd quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 267 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Down 0.7%

Shares of NYSE BMY opened at $56.60 on Friday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The stock’s fifty day simple moving average is $51.74 and its two-hundred day simple moving average is $48.06. The stock has a market capitalization of $115.22 billion, a PE ratio of 19.12, a price-to-earnings-growth ratio of 9.44 and a beta of 0.29. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same period in the previous year, the company posted $1.80 EPS. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a $0.63 dividend. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.5%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BMY shares. Morgan Stanley reaffirmed an “underweight” rating and set a $37.00 price target (up previously from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Scotiabank reiterated a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Guggenheim restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday, December 23rd. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $56.86.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.